Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for January 27, 2012 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



An Ingredient in Medication Taken by Women is Causing Birth Defects
Topamax, an anti-seizure, migraine headache and weight-loss drug is linked to birth defects in children whose mothers took the drug before and during the first trimester of pregnancy. 
x-small text small text medium text large text


    January 27, 2012 /24-7PressRelease/ -- An Ingredient in Medication Taken by Women is Causing Birth Defects

It is such an exciting time -- preparing for the birth of a child. An expecting mother carefully monitors what she eats and drinks in order to maximize the health of the child growing inside of her. She prepares the nursery, engages in a safe level of exercise and sees her doctor on a regular basis, all with the hopes of delivering a healthy, bouncing baby. Unfortunately, a medication she took prior to her pregnancy or during the first trimester of her pregnancy could produce devastating side effects on her unborn child.

Topiramate -- brand name Topamax -- is an ingredient in a number of drugs used to treat the following conditions:
-Seizures
-Epilepsy
-Migraine headaches
-Weight loss
-Bipolar disorder
-Post-traumatic stress syndrome (clinical trials only)

In the 1990s, the FDA approved Topamax as an anticonvulsant (anti-seizure) medication and for treatment of migraine headaches. However, in 2008, a medical study came out showing that women who took the drug before or during pregnancy had a greatly increased risk of having children with birth defects. In 2011, the FDA issued a medication guide stating that Topamax can harm an unborn baby, creating a high risk for the following defects:
-Cleft palette
-Cleft lip
-Metabolic acidosis -- producing too much acid in the body
-Other oral deformities, malformations and craniofacial defects

Despite the warnings, Topamax continues to be used as an ingredient in a number of drugs. Most recently, experimental weight-loss pill Qnexa has been developed with Topamax as a main ingredient. The FDA required Vivus Inc., the maker of the drug, to analyze existing database information to determine the risk of oral cleft in children whose mothers took Topamax during or prior to their pregnancies. The analysis revealed that the risk is higher, especially for those women who take the drug during the initial stages of pregnancy, including those who do not yet know they are pregnant.

Despite the increased risk, should the FDA approve the drug early this year, the maker of the drug will not be required to include warnings for all women capable of becoming pregnant but only warn those who already are.

If you have taken Topamax and are concerned about its side effects, or if you have a child with an oral deformity or malformation, consult with a lawyer knowledgeable about birth defects and dangerous drugs.

Article provided by Miller Weisbrod, L.L.P.
Visit us at http://www.badpharmalawyer.com/


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from FL Web Advantage:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
FL Web Advantage

E-Mail: Email us Here
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.